# US 11,027,002 B2 · Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,027,002 B2
- Document ID: US11027002B2
- Status: Granted
- Kind: B2
- Application number: 17/116,845
- Filed: 2020-12-09
- Published: 2021-04-01
- Granted: 2021-06-08
- Earliest claimed: 2015-04-24
- Assignees: Immatics Biotechnologies GmbH
- Applicants: Immatics Biotechnologies GmbH
- Inventors: Andrea Mahr; Toni Weinschenk; Oliver Schoor; Jens Fritsche; Harpreet Singh; Claudia Wagner; Julia Leibold; Colette Song
- Web page: https://patentgrep.com/patent/US11027002B2

## CPC

- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 39/0011: {Cancer antigens}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/428: {Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor}
- A61P 35/00: Antineoplastic agents
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- C07K 16/30: from tumour cells
- C12N 5/0636: {T lymphocytes}
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- C12N 2501/50: Cell markers; Cell surface determinants
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/156: Polymorphic or mutational markers
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

## Claims

### Claim 1

A method of eliciting an immune response in a patient who has cancer overexpressing a COL12A1 polypeptide comprising the amino acid sequence SYSIGIANF (SEQ ID NO: 57), comprising administering to said patient a population of activated T cells that kill the cancer cells,
wherein the activated T cells are cytotoxic CD8+ T cells produced by contacting T cells with an antigen presenting cell that presents a peptide consisting of the amino acid sequence of SYSIGIANF (SEQ ID NO: 57) in a complex with an MHC class I molecule on the surface of the antigen presenting cell in vitro, for a period of time sufficient to activate said T cell,
wherein the cancer is lung cancer or brain cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the T cells are autologous to the patient.

### Claim 3 (depends on 1)

The method of claim 1, wherein the T cells are obtained from a healthy donor.

### Claim 4 (depends on 1)

The method of claim 1, wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.

### Claim 5 (depends on 1)

The method of claim 1, wherein the activated T cells are expanded in vitro.

### Claim 6 (depends on 5)

The method of claim 5, wherein the expansion is in the presence of an anti-CD28 antibody and IL-12.

### Claim 7 (depends on 1)

The method of claim 1, wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide.

### Claim 8 (depends on 7)

The method of claim 7, wherein the antigen presenting cell is a dendritic cell or a macrophage.

### Claim 9 (depends on 1)

The method of claim 1, wherein the population of activated T cells are administered in the form of a composition.

### Claim 10 (depends on 9)

The method of claim 9, wherein the composition further comprises an adjuvant.

### Claim 11 (depends on 10)

The method of claim 10, wherein the adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, Sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, and particulate formations with poly(lactide coglycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

### Claim 12 (depends on 1)

The method of claim 1, wherein the MHC molecule is HLA-A*24.

### Claim 13 (depends on 1)

The method of claim 1, wherein the immune response is cytotoxic T cell response.

### Claim 14 (depends on 11)

The method of claim 11, wherein the adjuvant comprises IL-2.

### Claim 15 (depends on 11)

The method of claim 11, wherein the adjuvant comprises IL-7.

### Claim 16 (depends on 11)

The method of claim 11, wherein the adjuvant comprises IL-12.

### Claim 17 (depends on 11)

The method of claim 11, wherein the adjuvant comprises IL-15.

### Claim 18 (depends on 11)

The method of claim 11, wherein the adjuvant comprises IL-21.

### Claim 19 (depends on 1)

The method of claim 1, wherein the cancer is lung cancer.

### Claim 20 (depends on 1)

The method of claim 1, wherein the cancer is brain cancer.